LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Troika co-founder Jason Anderson's research on Vampire: The Masquerade source material and fansites found that the game's main attraction was character interaction and involvement in the vampire societies, not statistics and powers. Troika tried to remain faithful to the pen-and-paper role-playing game, hoping not to alienate the game's fans, but rules designed for multiple players did not translate well to single-player computer game design. The team attempted to discover which elements could work equally well in pen-and-paper and computer games. However, although much of the character system and attributes were translated, not all the attributes (such as "knowledge of law") made sense in the computer game. Of 30 pen-and-paper abilities, 15 reached the final design. Another difficult area was feats. Although common feats worked well, with a random chance of success or failure, uncommon ones would appear to fail more often. To avoid this, randomization was replaced by a degree of difficulty in accomplishing the feat. Although pen-and-paper falling damage is random, the computer game bases damage on the distance of the fall. The team's biggest challenge was adapting disciplines. The pen-and-paper version may require a little blood that requires a long time to use or have no blood cost and can be used at will; upgraded disciplines had additional requirements considered too confusing for a computer game.
== Synthesis == The oxygen atom in these molecules can in many cases be dispensed with as well; substitution of sulfur for nitrogen affords a molecule whose salient biologic properties are those of a sedative and tranquilizer.
Humans cannot catch warts from toads or other animals; the bumps on a toad are not warts. Warts on human skin are caused by human papillomavirus, which is known to affect only humans. Cracking one's knuckles does not cause osteoarthritis. In people with eczema, bathing does not dry the skin as long as a moisturizer is applied soon after. If moisturizer is not applied after bathing, then the evaporation of water from the skin can result in dryness. There have never been any programs in the US that provide access to dialysis machines in exchange for pull tabs on beverage cans. This rumor has existed since at least the 1970s, and usually cites the National Kidney Foundation as the organization offering the program. The Foundation itself has denied the rumor, noting that dialysis machines are primarily funded by Medicare. Rhinoceros horn in powdered form is not used as an aphrodisiac in traditional Chinese medicine as Cornu Rhinoceri Asiatici (犀角, xījiǎo, "rhinoceros horn"). It is prescribed for fevers and convulsions, a treatment not supported by evidence-based medicine. Leprosy is not auto-degenerative as commonly supposed, meaning that it will not (on its own) cause body parts to be damaged or fall off. Leprosy causes rashes to form and may degrade cartilage and, if untreated, inflame tissue. In addition, leprosy is only mildly contagious, partly because 95% of those infected with the mycobacteria that cause leprosy do not develop the disease.
Sources: en.wikipedia.org
As anti-angiogenic cancer therapies have achieved widespread use, there has been increased interest in non-invasive monitoring of angiogenesis. One of the most extensively examined targets of angiogenesis is integrin αVβ3. Radiolabeled peptides containing RGD show high affinity and selectivity for integrin αVβ3 and are being investigated as tools to monitor treatment response of tumors via PET imaging. These include 18F-Galacto-RGD, 18F-Fluciclatide-RGD, 18F-RGD-K5, 68Ga-NOTA-RGD, 68Ga-NOTA-PRGD2, 18F-Alfatide, 18F-Alfatide II, and 18F-FPPRGD2. In a meta-analysis of studies using PET/CT in patients with cancer, it was shown that this diagnostic method may be very useful for detecting malignancies and predicting short-term outcomes, although larger-scale studies are needed.
Homologous recombination OB-fold protein is a protein which in humans is encoded by the gene HROB (previously C17orf53). It is involved in the repair of DNA, and is most highly expressed in the digestive system and female reproductive system. Pathogenic variants have been associated with female reproductive system dysfunction, including premature menopause and ovarian dysgenesis. Neighboring genes of HROB are that of RNU6-131, RNA U6 Small Nuclear 131 Pseudogene, and ASB16, Ankyrin Repeat And SOCS Box Containing 16. HROB has been observed to be expressed ubiquitously across almost all tissue types of the body, but with highest expression found in the duodenum and fallopian tubes, while in the brain there was little region specificity. However, inconsistencies between antibody staining and RNA expression make interpretation of these results difficult.
This domain is also found in ghrelin, a growth hormone secretagogue synthesised by endocrine cells in the stomach. Ghrelin stimulates growth hormone secretagogue receptors in the pituitary. These receptors are distinct from the growth hormone-releasing hormone receptors, and, thus, provide a means of controlling pituitary growth hormone release by the gastrointestinal system. Erythromycin has an advantage over metoclopramide in gastric emptying due to lack of central nervous system side-effects. It is not approved by FDA to use for gastric emptying. For short duration for patients with diabetes and for those that must clear the stomach for any procedure, it may be used based on the physician's discretion with full understanding that it is not approved by FDA for this use. GHRL; Motilin; Motilin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_26". Essentials of Human Physiology. Archived from the original on 2016-03-24.
Molybdenum-99 is produced commercially by intense neutron-bombardment (i.e. fission) of a highly purified uranium-235 target, followed rapidly by extraction. It is used as a parent radioisotope in technetium-99m generators to produce the even shorter-lived daughter isotope technetium-99m, which is used in approximately 40 million medical procedures annually. A common misunderstanding or misnomer is that 99Mo is used in these diagnostic medical scans, when actually it has no role in the imaging agent or the scan itself. In fact, 99Mo co-eluted with the 99mTc (also known as breakthrough) is considered a contaminant and is minimised to adhere to the appropriate USP (or equivalent) regulations and standards. The IAEA recommends that 99Mo concentrations exceeding more than 0.15 μCi/mCi 99mTc or 0.015% should not be administered for usage in humans. Typically, quantification of 99Mo breakthrough is performed for every elution when using a 99Mo/99mTc generator during QA-QC testing of the final product. There are alternative routes for generating 99Mo that do not require a fissionable target, such as high or low enriched uranium (i.e., HEU or LEU). Some of these include accelerator-based methods, such as proton bombardment or photoneutron reactions on enriched 100Mo targets. Historically, 99Mo generated by neutron capture on natural isotopic molybdenum or enriched 98Mo targets was used for the development of commercial 99Mo/99mTc generators. The neutron-capture process was eventually superseded by fission-based 99Mo that could be generated with much higher specific activities.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.